Johnson & Johnson JNJ announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving ...

I am proposing that all companies currently engaged in developing biosimilars join hands with their regulatory and scientific ...

In the latest episode of Oncology Unscripted, Dr. John Marshall addresses critical issues concerning the dosing practices in oncology, particularly questioning the prevailing approach of using maximum ...

The CHMP has simultaneously recommended the approval of a Type II indication extension for amivantamab in the same combination treatment. The CHMP positive opinions for the approval and the Type II ...

Hatim Husain, MD, discusses how the implementation of proactive prophylaxis strategies for patients taking amivantamab, ...

Assetmark Inc. boosted its stake in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 16.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 82,629 shares of ...

Jemma knew something was wrong when she couldn't get off the floor."I always kind of had that lower back pain there," the ...

including a challenge from Johnson & Johnson’s bispecific EGFR/MET-targeting antibody Rybrevant (amivantamab). Rybrevant is currently approved only for a subcategory of EGFR+ NSCLC patients with ...

That alliance also generated Darzalex (daratumumab) – Janssen's $4.1 billion myeloma blockbuster – as well as Rybrevant (amivantamab), its first bispecific which has been approved to treat ...

Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

The net asset value (NAV) per unit of the Baltic Horizon Fund (the Fund) amounted to EUR 0.7080 at the end of October 2024 (0.7099 as of 30 September 2024). The month-end total net asset value of the ...